PHARMACOKINETIC ANALYSIS OF TOPOTECAN AFTER SUPERSELECTIVE OPHTHALMIC ARTERY INFUSION AND PERIOCULAR ADMINISTRATION IN A PORCINE MODEL
Authors:
- Emiliano BuitragoEBEmiliano Buitrago
- Alejandro CecilianoACAlejandro Ceciliano
- Adriana C. FandinoAFAdriana C. Fandino
- Marcelo AspreaMAMarcelo Asprea
- Sergio SierreSSSergio Sierre
- David H. AbramsonDADavid H. Abramson
- Guillermo F. BramugliaGBGuillermo F. Bramuglia
- Guillermo L. ChantadaGCGuillermo L. Chantada
- 1 February 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Retina
- Vol. 32 (2) , 387-395
Abstract
To characterize the vitreous and plasma pharmacokinetics of topotecan after ophthalmic artery infusion (OAI) subsequent to superselective artery catheterization and to compare it with periocular injection (POI). The ophthalmic artery of 4 pigs was catheterized and 1 mg of topotecan infused over a period of 30 minutes. The contralateral eye was subsequently used for administering topotecan by POI. Serial vitreous specimens were obtained by microdialysis and plasma samples collected and assayed for total and lactone topotecan. Maximum total topotecan concentration in the vitreous (median, range) was significantly higher after OAI compared with POI (131.8 ng/mL [112.9-138.7] vs. 13.6 ng/mL [5.5-15.3], respectively; P < 0.005). Median vitreous exposure calculated as area under the curve for total topotecan attained after OAI was significantly higher than after POI (299.8 ng·hour/mL [247.6-347.2] and 48.9 ng·hour/mL [11.8-63.4], respectively; P < 0.05). The vitreous to plasma exposure ratio was 29 after OAI and 3.4 after POI. Systemic exposure for total topotecan was low after both modalities of administration, with a trend to be lower after OAI compared with POI (10.6 ng·hour/mL [6.8-13.4] vs. 18.7 ng·hour/mL [6.3-21.7]; P = 0.54). Superselective OAI resulted in significantly higher vitreous concentrations and exposure and a trend toward lower systemic exposure than POI.Keywords
This publication has 27 references indexed in Scilit:
- A Phase I Study of Periocular Topotecan in Children with Intraocular RetinoblastomaInvestigative Ophthalmology & Visual Science, 2009
- Recent Perspectives in Ocular Drug DeliveryPharmaceutical Research, 2008
- Drug transport in corneal epithelium and blood–retina barrier: Emerging role of transporters in ocular pharmacokineticsAdvanced Drug Delivery Reviews, 2006
- Delivery from Episcleral ExoplantsInvestigative Ophthalmology & Visual Science, 2006
- Immunohistochemical Detection of Multidrug-Resistant Protein Expression in Retinoblastoma Treated by Primary EnucleationInvestigative Ophthalmology & Visual Science, 2006
- Response of Retinoblastoma With Vitreous Tumor Seeding to Adenovirus-Mediated Delivery of Thymidine Kinase Followed by GanciclovirJournal of Clinical Oncology, 2005
- UPDATE ON RETINOBLASTOMARetina, 2004
- Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleationOphthalmology, 2004
- Eye-Preservation Treatment of Retinoblastoma with Vitreous SeedingJapanese Journal of Clinical Oncology, 2003
- A phase I/II study of subconjunctival carboplatin for intraocular retinoblastomaOphthalmology, 1999